Entegrion Resusix Dose Response Phase 2 - $48,650

Sponsored by Entegron, Inc., led by James Manning, MD

The primary objective for the Entegrion Resusix Dose Response Study is to quantitatively compare the effectiveness of Resusix© to restore intravascular coagulation factors following hemorrhage. Additionally, Entegrion would like to test the efficacy of new surface hemostatics currently under development by the company.

Filed under: